{"id":"https://openalex.org/G786299790","display_name":"Combined anti-cancer immunotherapy based on the ability of immune responses in aged hosts","description":"The in vivo growth of murine colon carcinoma CT26 was more rapid in aged mice compared to young mice, and the serum levels of IL-6 were elevated in aged mice. In addition, aged mice showed lower response to anti-cancer vaccine by inactivated cancer cells compared to young mice. On the other hand, we examined the immune responses to murine renal carcinoma RENCA expressing human CA9 (hCA9) as a non-self antigen. As a result, young mice rejected RENCA/hCA9 and human CA9-recognizing CD8+ T cells and CD4+ T cells were induced in such mice. In addition, aged mice allowed RENCA/hCA9 to grow in vivo but combined immunotherapy with immune checkpoint blockade therapy with chemotherapy exerted significant antitumor effects even in aged mice.","funder_award_id":"17K07217","funder":{"id":"https://openalex.org/F4320334764","display_name":"Japan Society for the Promotion of Science","doi":"https://doi.org/10.13039/501100001691"},"funded_outputs":["https://openalex.org/W31784453","https://openalex.org/W2743167573","https://openalex.org/W2790006183","https://openalex.org/W2804338027","https://openalex.org/W2956087042","https://openalex.org/W2990635313","https://openalex.org/W3013925740","https://openalex.org/W3027243916","https://openalex.org/W3080894620","https://openalex.org/W3174433092"],"funded_outputs_count":10,"parent_awards":[],"sub_awards":[],"sub_awards_count":0,"amount":4810000.0,"currency":"JPY","amount_usd":43014.4,"amount_usd_basis":"daily_rate","recipients":[],"recipient_countries":[],"recipient_regions":[],"research_scope":{"is_research":true,"basis":"funder_default","tier":1},"funding_type":"research","funder_scheme":"Grant-in-Aid for Scientific Research (C)","start_date":"2017-04-01","end_date":"2020-03-31","start_year":2017,"end_year":2020,"landing_page_url":"https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-17K07217/","doi":null,"provenance":"kaken","lead_investigator":{"given_name":"Mamoru","family_name":"Harada","orcid":null,"role_start":null,"affiliation":{"name":"Shimane University","country":"Japan","ids":[{"id":"https://nrid.nii.ac.jp/nrid/1000050260716","type":"nrid","asserted_by":"kaken"}]},"author":{"id":"https://openalex.org/A5000210861","display_name":"Mamoru Harada","orcid":"https://orcid.org/0000-0002-9737-0360"},"institutions":[{"id":"https://openalex.org/I169016828","display_name":"Shimane University","ror":"https://ror.org/01jaaym28","country_code":"JP","type":"education","lineage":["https://openalex.org/I169016828"]}]},"co_lead_investigator":null,"investigators":null,"works_api_url":"https://api.openalex.org/works?filter=awards.id:G786299790","primary_topic":{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.563,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.563,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.4172,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.014,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.737},{"id":"https://openalex.org/keywords/aging","display_name":"aging","score":0.788},{"id":"https://openalex.org/keywords/aged-mice","display_name":"aged mice","score":0.668},{"id":"https://openalex.org/keywords/cancer-vaccines","display_name":"cancer vaccines","score":0.718},{"id":"https://openalex.org/keywords/interleukin-6","display_name":"interleukin-6","score":0.7},{"id":"https://openalex.org/keywords/ct26-cells","display_name":"CT26 cells","score":0.769},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.903},{"id":"https://openalex.org/keywords/cd4-t-cells","display_name":"CD4+ T cells","score":0.998},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.97},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.625},{"id":"https://openalex.org/keywords/chemotherapy","display_name":"chemotherapy","score":0.608},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.768}],"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"institution_awarded":[{"id":"https://openalex.org/I169016828","display_name":"Shimane University","ror":"https://ror.org/01jaaym28","country_code":"JP","type":"education","lineage":["https://openalex.org/I169016828"]}],"updated_date":"2026-11-13T03:01:57.000Z","created_date":"2026-07-13T04:17:19.000Z"}
